Cassava Sciences And Alzheimer's Disease: Unravelling The Data

Jan. 30, 2023 2:20 AM ETCassava Sciences, Inc. (SAVA)565 Comments
Lane Simonian profile picture
Lane Simonian


  • Most of those who improved while taking Cassava Sciences' drug candidate simufilam had mild cognitive impairment.
  • Most of those who declined while taking simufilam had mild Alzheimer's Disease.
  • Until the FDA decides on simufilam in a couple of years or more, Cassava Sciences is likely to trade within a narrow range.
green ball of yarn on white background

arcimages/E+ via Getty Images

Cassava Sciences (NASDAQ:SAVA) recently released results for its open label extension trial for simufilam, which it proclaimed as positive. Some investors, though, were unimpressed. Part of the dour reaction was that the percentage of people who improved while

This article was written by

Lane Simonian profile picture
Retired history instructor. Alzheimer's disease researcher for the past decade.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs.  This advice is informed by  a background in biology (conservation, ecology, evolution, environmental science, and biochemistry) and seventeen years of a very in depth review of the research on Alzheimer's disease.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (565)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.